Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs

Authors

Andrew J Kinloch
Faiyaz Rahman
Bahriye Karakas
Muhammad Shahid
Bora Lim
Stephanie J Bouley
James A Walker
Erinna F Lee
Walter D Fairlie
Kevin R Kelly
Michael H Cardone

Publication Date

5-31-2025

Journal

Cancers

DOI

10.3390/cancers17111852

PMID

40507334

PMCID

PMC12153628

PubMedCentral® Posted Date

5-31-2025

PubMedCentral® Full Text Version

Post-print

Abstract

One of the hallmarks of cancer cells is their failure to respond to the cellular mechanism of apoptosis. The B-cell lymphoma 2 (BCL-2) family of proteins regulate apoptosis. Their ability to do so can be measured using several methods that in turn anticipate the fate of the cancer cell in response to apoptosis-inducing treatment. These assays ultimately identify the readiness of the cancer cell to undergo apoptosis, which is referred to as the mitochondrial priming state. These metrics, however, have been challenging to implement in the clinic.

Keywords

apoptosis, BH3 domain, PRIMAB, AML, mitochondrial priming, BH3 mimetics, flow cytometry

Published Open-Access

yes

Recommended Citation

Kinloch, Andrew J; Rahman, Faiyaz; Karakas, Bahriye; et al., "Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs" (2025). Faculty, Staff and Student Publications. 4739.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4739